Progress in surgical treatment of non-small cell lung cancer invading the chest wall

doi:10.3877/cma.j.issn.2095-8773.2022.03.05

Abstract

Abstract:

Non-small cell lung cancer (NSCLC) invading the chest wall was once considered to have poor prognosis. Pulmonary resection combined with lymph node dissection, chest wall resection and chest wall reconstruction have been the main surgical methods. However, unified standard has not been determined for preoperative neoadjuvant therapy, surgical and reconstruction methods, and postoperative adjuvant therapy. In recent years, with the development of surgical resection methods and chest wall reconstruction technology, complete tumor resection is no longer a challenge. Tumor targeted therapy and immunotherapy have become new directions for neoadjuvant therapy and postoperative adjuvant therapy research, which is expected to further improve the prognosis of patients with NSCLC invading the chest wall. This article summarizes the latest research progress in surgical and reconstruction methods, preoperative neoadjuvant and postoperative adjuvant therapy for patients with resectable non-small cell lung cancer invading the chest wall, in order to provide help for the treatment decision of patients with this type of cancer.

Key words: Chest wall invasion, Non-small cell lung cancer, Chest wall reconstruction

Xiao Liang, Lei Wang, Tao Jiang. Progress in surgical treatment of non-small cell lung cancer invading the chest wall[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 157-163.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2022.03.05

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2022/V09/I03/157

References 58

1	Riquet M，Arame A，Le Pimpec Barthes F．Non-small cell lung cancer invading the chest wall[J]．Thorac Surg Clin，2010，20（4）：519-527．
2	Wang L，Yan X，Zhao J，et al．Expert consensus on resection of chest wall tumors and chest wall reconstruction[J]．Transl Lung Cancer Res，2021，10（11）：4057-4083．
3	Yokoi K，Taniguchi T，Usami N，et al．Surgical management of locally advanced lung cancer[J]．Gen Thorac Cardiovasc Surg，2014，62（9）：522-530．
4	Downey RJ，Martini N，Rusch VW，et al．Extent of chest wall invasion and survival in patients with lung cancer[J]．Ann Thorac Surg，1999，68（1）：188-193．
5	仲佳．《CSCO非小细胞肺癌诊疗指南2021》更新要点解读[J]．实用肿瘤杂志，2022，37（1）：8-15．
6	Ucvet A，Yazgan S，Gursoy S，et al．Prognosis of Resected Non-small Cell Lung Cancer with Ipsilateral Pulmonary Metastasis[J]．Thorac Cardiovasc Surg，2020，68（2）：176-182．
7	Lee CY，Byun CS，Lee JG，et al．The prognostic factors of resected non-small cell lung cancer with chest wall invasion[J]．World J Surg Oncol，2012，10：9．
8	Suzuki M，Yoshida S，Moriya Y，et al．Surgical outcomes of newly categorized peripheral T3 non-small cell lung cancers: comparisons between chest wall invasion and large tumors （>7 cm）[J]．Interact Cardiovasc Thorac Surg，2010，11（4）：420-424．
9	Voltolini L，Rapicetta C，Luzzi L，et al．Lung cancer with chest wall involvement: predictive factors of long-term survival after surgical resection[J]．Lung Cancer，2006，52（3）：359-364．
10	Coster JN，Groth SS．Surgery for Locally Advanced and Oligometastatic Non-Small Cell Lung Cancer[J]．Surg Oncol Clin N Am，2020，29（4）：543-554．
11	Facciolo F，Cardillo G，Lopergolo M，et al．Chest wall invasion in non-small cell lung carcinoma：a rationale for en bloc resection[J]．J Thorac Cardiovasc Surg，2001，121（4）：649-656．
12	Otsuka S，Hiraoka K，Ohtaka K，et al．Small-sized peripheral squamous cell lung carcinoma with chest wall invasion[J]．Respir Med Case Rep，2022，36：101589．
13	Santos HT，Lopes AJ，Higa C，et al．Lung cancer with chest wall invasion：retrospective analysis comparing en-bloc resection and 'resection in bird cage’[J]．J Cardiothorac Surg，2014，9：57．
14	Doddoli C，D’Journo B，Le Pimpec-Barthes F，et al．Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies[J]．Ann Thorac Surg，2005，80（6）：2032-2040．
15	Hanagiri T，Shinohara S，Takenaka M，et al．Clinical Characteristics of Resected T3 Non-small Cell Lung Cancer Characterized by Parietal Pleural Invasion or Chest Wall Invasion[J]．Indian J Surg，2014，76（5）：354-358．
16	Akata S，Kajiwara N，Park J，et al．Evaluation of chest wall invasion by lung cancer using respiratory dynamic MRI[J]．J Med Imaging Radiat Oncol，2008，52（1）：36-39．
17	Tahiri M，Khereba M，Thiffault V，et al．Preoperative assessment of chest wall invasion in non-small cell lung cancer using surgeon-performed ultrasound[J]．Ann Thorac Surg，2014，98（3）：984-989．
18	Sripathi S，Mahajan A．Comparative study evaluating the role of color Doppler sonography and computed tomography in predicting chest wall invasion by lung tumors[J]．J Ultrasound Med，2013，32（9）：1539-1546．
19	Collaud S，Fadel E，Schirren J，et al．En Bloc Resection of Pulmonary Sulcus Non-small Cell Lung Cancer Invading the Spine: A Systematic Literature Review and Pooled Data Analysis[J]．Ann Surg，2015，262（1）：184-188．
20	Jones GD，Caso R，No JS，et al．Prognostic factors following complete resection of non-superior sulcus lung cancer invading the chest wall[J]．Eur J Cardiothorac Surg，2020，58（1）：78-85．
21	王磊，李靖，钟代星．胸壁肿瘤切除及胸壁重建手术中国专家共识(2018版)[J]．中国胸心血管外科临床杂志，2019，26（1）：1-7．
22	Kawaguchi K，Mori S，Usami N，et al．Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients[J]．Lung Cancer，2009，64（1）：41-44．
23	张茂增，胡为才，姬弘涛．胸壁切除术和非胸壁切除术治疗非小细胞肺癌的效果对比[J]．右江民族医学院学报，2020，42（2）：212-215．
24	陈重．侵犯胸壁的非小细胞肺癌的外科治疗[J]．河南医学研究，2012，21（3）：285-286．
25	Scarnecchia E，Liparulo V，Capozzi R，et al．Chest wall resection and reconstruction for tumors: analysis of oncological and functional outcome[J]．J Thorac Dis，2018，10（Suppl 16）：S1855-S1863．
26	Lanuti M．Surgical Management of Lung Cancer Involving the Chest Wall[J]．Thorac Surg Clin，2017，27（2）：195-199．
27	Matsuoka H，Nishio W，Okada M，et al．Resection of chest wall invasion in patients with non-small cell lung cancer[J]．Eur J Cardiothorac Surg，2004，26（6）：1200-1204．
28	Magdeleinat P，Alifano M，Benbrahem C，et al．Surgical treatment of lung cancer invading the chest wall: results and prognostic factors[J]．Ann Thorac Surg，2001，71（4）：1094-1099．
29	Berry MF，Onaitis MW，Tong BC，et al．Feasibility of hybrid thoracoscopic lobectomy and en-bloc chest wall resection[J]．Eur J Cardiothorac Surg，2012，41（4）：888-892．
30	Demmy TL，Yendamuri S，Hennon MW，et al．Thoracoscopic maneuvers for chest wall resection and reconstruction[J]．J Thorac Cardiovasc Surg，2012，144（3）：S52-S57．
31	Muguruza I，Aranda JL，García-Yuste M．Treatment of lung cancer with chest wall invasion[J]．Arch Bronconeumol，2011，47 Suppl 1：27-32．
32	Zhang Y，Li JZ，Hao YJ，et al．Sternal tumor resection and reconstruction with titanium mesh：a preliminary study[J]．Orthop Surg，2015，7（2）：155-160．
33	Weyant MJ，Bains MS，Venkatraman E，et al．Results of chest wall resection and reconstruction with and without rigid prosthesis[J]．Ann Thorac Surg，2006，81（1）：279-285．
34	Scarnecchia E，Liparulo V，Capozzi R，et al．Chest wall resection and reconstruction for tumors: analysis of oncological and functional outcome[J]．J Thorac Dis，2018，10（Suppl 16）：S1855-S1863．
35	Wiegmann B，Zardo P，Dickgreber N，et al．Biological materials in chest wall reconstruction: initial experience with the Peri-Guard Repair Patch[J]．Eur J Cardiothorac Surg，2010，37（3）：602-605．
36	Wang L，Huang L，Li X，et al．Three-Dimensional Printing PEEK Implant: A Novel Choice for the Reconstruction of Chest Wall Defect[J]．Ann Thorac Surg，2019，107（3）：921-928．
37	Kumar N，Malik PS，Bharati SJ，et al．Primary lung cancer with chest wall involvement: Outcomes of a multimodality management approach[J]．Lung India，2021，38（4）：338-342．
38	Sauerbier M，Dittler S，Kreutzer C．Microsurgical chest wall reconstruction after oncologic resections[J]．Semin Plast Surg，2011，25（1）：60-69．
39	Brown LM，Cooke DT，David EA．Adjuvant Chemotherapy Does Not Improve Survival for Lung Cancer With Chest Wall Invasion[J]．Ann Thorac Surg，2017，104（6）：1798-1804．
40	Berriochoa C，Videtic GM，Woody NM，et al．Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion[J]．Clin Lung Cancer，2016，17（6）：595-601．
41	Muñoz-Largacha JA，Rao SR，Brinckerhoff LH，et al．Induction chemoradiation is associated with improved survival in chest wall invasion lung cancer[J]．Tumori，2019，105（4）：331-337．
42	Kennedy WR，Gabani P，Nikitas J，et al．Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy[J]．Clin Transl Radiat Oncol，2019，16：1-6．
43	Stoelben E，Ludwig C．Chest wall resection for lung cancer: indications and techniques[J]．Eur J Cardiothorac Surg，2009，35（3）：450-456．
44	Wang Meina，Herbst Roy S.，Boshoff Chris，等．非小细胞肺癌的个体化治疗进展[J]．中国肺癌杂志，2022，25（3）：219-236．
45	Zhong WZ，Chen KN，Chen C，et al．Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer （EMERGING-CTONG 1103）：A Randomized Phase II Study[J]．J Clin Oncol，2019，37（25）：2235-2245．
46	Liu SY，Zhang JT，Zeng KH，et al．Perioperative targeted therapy for oncogene-driven NSCLC[J/OL]．Lung Cancer，2022，[Epub ahead of print]．
47	Sun L，Guo YJ，Song J，et al．Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC：A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials[J]．Front Oncol，2020，10：586596．
48	Zhao Z，Gao Y，Xue Q，et al．Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer：A Systematic Review[J]．Target Oncol，2021，16（4）：425-434．
49	Yeh J，Marrone KA，Forde PM．Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer[J]．J Thorac Dis，2018，10（Suppl 3）：S451-S459．
50	Wang J，Li J，Cai L，et al．The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer[J]．Ann Transl Med，2021，9（6）：486．
51	Janjigian YY，Shitara K，Moehler M，et al．First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma （CheckMate 649）: a randomised, open-label, phase 3 trial[J]．Lancet，2021，398（10294）：27-40．
52	Douillard JY，Rosell R，De Lena M，et al．Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial[J]．Int J Radiat Oncol Biol Phys，2008，72（3）：695-701．
53	Le Pechoux C，Pourel N，Barlesi F，et al．Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART)：an open-label, randomised, phase 3 trial[J]．Lancet Oncol，2022，23（1）：104-114．
54	朱晓霞，苏俊威．精确术后放疗对pⅢA-N2非小细胞肺癌患者在完全切除和辅助化疗后生存和失败模式的影响[J]．循证医学，2020，20（6）：325-328．
55	Gao SJ，Corso CD，Blasberg JD，et al．Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall[J]．Clin Lung Cancer，2017，18（2）：169-177.e4．
56	Yue D，Xu S，Wang Q，et al．Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer （EVAN）:a randomised, open-label, phase 2 trial[J]．Lancet Respir Med，2018，6（11）：863-873．
57	Chen CY，Fares CM，Shin DS．Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report[J]．J Med Case Rep，2021，15（1）：216．
58.	Felip E，Altorki N，Zhou C，et al．Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer （IMpower010）：a randomised, multicentre, open-label, phase 3 trial[J]．Lancet，2021，398（10308）：1344-1357．

[1]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[2]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[3]	Yuan Wang, Yi Yang, Yunfei Mou, Fuqiang Ren, Xin Huang. Analysis of postoperative osimertinib targeted therapy in patients with resectable non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 657-660.
[4]	Ling Ma, Yinglong Li, Na Yue, Lifei Yang. Expression and clinical value of differential proteins in exosomes from non-small cell lung cancer [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(03): 327-330.
[5]	Xiaoqin Weng, Jiayang Qin, Yang Zhang, Jin Cui, Hong Shen. Effect of HIF-1α/VEGF-VEGFR2/Nrp-1 on Treg proliferation in NSCLC patients [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 717-722.
[6]	Zhiguo Yu, Bo Gong, Weihua Lu, Minfang Li. Silencing HIF-1α regulates MAPK/ERK pathway and inhibits metastasis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 573-578.
[7]	Rui Xu, Yong Qian, Haiyan Zhang. Study on the mechanism of miR-515-5p enhanced the cisplatin sensitivity of NSCLC A549/DDP cells via targeting RING1 [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 559-563.
[8]	Xuan Wang, Lichun Cui, Shengqiang Dang. Effect of apatinib and Erica on the expression of immune cell surface molecules in patients with NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(05): 554-558.
[9]	Jiu Yang, Mei Hong, Zhiyuan Liu, Nuo Zhu. Yiqi Chutan recipe combined with chemotherapy for treatment of patients with advanced non-small cell lung cancer: short-term curative effect and impact on serum levels of IL-2 and TNF-α and immune function [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 948-953.
[10]	Bo Zhang, Bo Jin. Progress in research of Met as a target in non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 797-800.
[11]	Jingxiu Niu, Lihong Zhang, Hui Wang. Clinical study on the improvement of adverse reactions related to paclitaxel combined with cisplatin chemotherapy in advanced non-small cell lung cancer by grey screening method [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 774-778.
[12]	Kexin Tang, Xi Lin, Hong Shan. Doxorubicin-loaded fluorescent carbon dots with PEI passivation inhibited proliferation, migration and invasion of non-small cell lung cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 131-136.
[13]	Leilei Shen, Yang Liu. The staging evolution and treatment strategies of stage ⅠB non-small cell lung cancer [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(04): 246-254.
[14]	Jianqiao Cai, Jing Huang, Lei Jiang. Double sleeve uniportal video-assisted thoracoscopic lobectomy—a retrospective study from shanghai pulmonary hospital [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2022, 09(03): 144-149.
[15]	Gang Jin, Keying Yao, Xingwei Shen, Long Ma, Zijiang Zhu. Efficacy of anti-PD-1/PD-L1 inhibitors versus docetaxel in the treatment of non-small cell lung cancer: a systematic review and meta-analysis [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2021, 08(04): 239-246.

Please choose a citation manager

Content to export